PRICING, REGULATION, AND COMPETITIVENESS - LESSONS FOR THE UNITED-STATES FROM THE JAPANESE PHARMACEUTICAL-INDUSTRY

被引：2

作者：

THOMAS, LG

机构：

[1] School of Business, Emory University, Atlanta, Georgia, 30322

来源：

PHARMACOECONOMICS | 1994年 / 6卷

关键词：

D O I：

10.2165/00019053-199400061-00016

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

This paper examines the nature of Japanese government regulation of pharmaceutical prices, and the impact of that regulation on the competitive performance of the Japanese industry. Possible implications for the reintroduction of pharmaceutical price controls in the US are also considered.

引用

页码：67 / 70

页数：4

共 8 条

[1]

Prescription drugs: companies typically charge more in the United States than in Canada, GAO/HRD-92-110, (1992)

[2]

Prescription drug prices: are we getting our money’s worth?, (1989)

[3]

Chew R., Teeling-Smith G., Wells R., Pharmaceuticals in seven nations, (1985)

[4]

Johnson C.A., MITI, MPT, and the telecom wars: how Japan makes policy for high technology, Politics and productivity: how Japan’s development strategy works, (1989)

[5]

Reich, Why the Japanese don’t export more pharmaceuticals: health policy as industrial policy, California Management Review, 32, pp. 124-150, (1990)

[6]

Kogut B., Country capabilities and the permeability of borders, Strategic Management Journal, 12, pp. 33-47, (1991)

[7]

Porter M.E., The competitive advantage of nations, (1990)

[8]

Thomas L.G., Spare the rod and spoil the industry: vigorous competition and vigorous regulation promote global competitive advantage, Working paper, (1993)

← 1 →